Intellia Therapeutics
March 02, 2026 -- Intellia Therapeutics, Inc. (NTLA), announced that the U.S. FDA has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy.
From Intellia Therapeutics

Intellia President and Chief Executive Officer John Leonard, M . . .